Literature DB >> 31786822

Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand.

Angela L Chiew1,2, David Reith3, Adam Pomerleau3, Anselm Wong4,5, Katherine Z Isoardi6,7, Jessamine Soderstrom8,9, Nicholas A Buckley2,10.   

Abstract

INTRODUCTION: Paracetamol is a common agent taken in deliberate self-poisoning and in accidental overdose in adults and children. Paracetamol poisoning is the commonest cause of severe acute liver injury. Since the publication of the previous guidelines in 2015, several studies have changed practice. A working group of experts in the area, with representation from all Poisons Information Centres of Australia and New Zealand, were brought together to produce an updated evidence-based guidance. MAIN RECOMMENDATIONS (UNCHANGED FROM PREVIOUS GUIDELINES): The optimal management of most patients with paracetamol overdose is usually straightforward. Patients who present early should be given activated charcoal. Patients at risk of hepatotoxicity should receive intravenous acetylcysteine. The paracetamol nomogram is used to assess the need for treatment in acute immediate release paracetamol ingestions with a known time of ingestion. Cases that require different management include modified release paracetamol overdoses, large or massive overdoses, accidental liquid ingestion in children, and repeated supratherapeutic ingestions. MAJOR CHANGES IN MANAGEMENT IN THE GUIDELINES: The new guidelines recommend a two-bag acetylcysteine infusion regimen (200 mg/kg over 4 h, then 100 mg/kg over 16 h). This has similar efficacy but significantly reduced adverse reactions compared with the previous three-bag regimen. Massive paracetamol overdoses that result in high paracetamol concentrations more than double the nomogram line should be managed with an increased dose of acetylcysteine. All potentially toxic modified release paracetamol ingestions (≥ 10 g or ≥ 200 mg/kg, whichever is less) should receive a full course of acetylcysteine. Patients ingesting ≥ 30 g or ≥ 500 mg/kg should receive increased doses of acetylcysteine.
© 2019 AMPCo Pty Ltd.

Entities:  

Keywords:  Chemical and drug induced liver injury; Drug overdose; Guidelines as topic; Toxicology

Year:  2019        PMID: 31786822     DOI: 10.5694/mja2.50428

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

1.  Delayed Acetaminophen Absorption Resulting in Acute Liver Failure.

Authors:  Huiling Tan; Paul Stathakis; Benoj Varghese; Nicholas A Buckley; Angela L Chiew
Journal:  Case Rep Crit Care       Date:  2022-05-07

2.  Stocks of paracetamol products stored in urban New Zealand households: A cross-sectional study.

Authors:  Eeva-Katri Kumpula; Pauline Norris; Adam C Pomerleau
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

3.  Medical toxicology experience: Poisoning consultations cases registry in Saudi Ministry of Health -2020 annual report.

Authors:  Fawaz A Al-Mousa; Ali M Gado; Afaf M Attia; Hany G Tammam
Journal:  Toxicol Rep       Date:  2021-08-02

4.  Antioxidant Mechanism of Renal and Hepatic Failure Prevention Related to Paracetamol Overdose by the Aqueous Extract of Amblygonocarpus andongensis Stem Bark.

Authors:  O Baponwa; A P Amang; C Mezui; B B Koubala; G T Siwe; V L Vandi; P V Tan
Journal:  Biomed Res Int       Date:  2022-07-21       Impact factor: 3.246

5.  Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.

Authors:  Hao Niu; Edmond Atallah; Ismael Alvarez-Alvarez; Raul J Andrade; M Isabel Lucena; Inmaculada Medina-Caliz; Guruprasad P Aithal; Cigdem Arikan
Journal:  Drug Saf       Date:  2022-08-25       Impact factor: 5.228

6.  Sensitivity of dose-estimations for acute acetaminophen overdose in predicting hepatotoxicity risk using the Rumack-Matthew Nomogram.

Authors:  Summon Chomchai; Pattaraporn Mekavuthikul; Jariya Phuditshinnapatra; Chulathida Chomchai
Journal:  Pharmacol Res Perspect       Date:  2022-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.